References
- Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998 May 7;12(7):F51-8. PubMed | Google Scholar
- Thienemann F, Sliwa, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013 Dec;34(46):3538-46 Epub 2013 Oct 14. PubMed | Google
Scholar
- Alassani A, Dovonou CA, Sossou E, Attinsounon CA, Gninkoun J, Wanvoegbe A et al. Prevalence, associated and predisposing factors of metabolic syndrome among people living with HIV on antiretroviral treatment in Porto Novo in 2014. Pan Afr Med J. 2015 Nov 24;22:296. PubMed | Google Scholar
- Dimodi HT, Etame C, Nguimkeng S, Mbappe FE, Ndoe, Tchinda et al. Prevalence of metabolic syndrome in HIV infected Cameroonian Patients. World Journal of AIDS. 2014; 4:84–92. Google Scholar
- Ayodele OE, Akinboro AO, Akinyemi SO, Adepeju AA, Akinremi OA, Alao CA, Popoola AA. Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab Syndr Relat Disord. 2012 Oct;10(5):373-9. Epub 2012 Jul 16. PubMed | Google Scholar
- Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS. 2008 Dec;22(12):941-5. PubMed | Google Scholar
- Zouiten, F, Ammari L, Chakroun M. Evaluation de la trithérapie antirétrovirale en Tunisie: étude multicentrique. Rev Tun Infectiol. 2007;1(1):12–19.
- Okome Nkoumou MML, Okome Essima R, Obiang Ndong GP, Okome Miame F. Bilan clinico-biologique des patients infectés par le VIH à la Fondation Jeanne Ebori de Libreville (2002-2005). Med Trop. 2007; 67: 357-362. Google Scholar
- Direction Générale de la Statistique et de la Comptabilité Nationale.
Enquête Multiples Indicators Cluster Survey in Togo. 2006; 10-12.
- Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d’experts. Médecine-Sciences, Ed Flammarion, Paris, p 402. 2002.
- Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AD, El-Sadr W et al. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 2007 Apr 26;356(17):1723-35. PubMed | Google Scholar
- Cabarrot T. Pathologies métaboliques du patient infecté par le VIH, Nouvelles thérapies, effets secondaires, et Stratégie de prise en charge. Mémoire d’université Montpellier N°170/2005.
- Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovuline in AIDS and advanced AIQS-related complex. Lancet. 1992; 339: 453-6. PubMed | Google Scholar
- Schambelen M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommandations_of an international AIDS society-USA panel. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. Google Scholar
- Passalaris J, Sepkowitz K, Glesby M. Coronary artery
disease and human immunodeficiency virus infection. Clin Infect Dis.
2000; 31: 787-97. PubMed | Google
Scholar
- Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001 Jan;32(1):130-9. Epub 2000 Dec 15. PubMed | Google Scholar